SQURPHARMA Stock Overview
Square Pharmaceuticals PLC. and its subsidiaries develop, manufacture, and market drugs for health care for various live species in Bangladesh.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 5/6 |
Rewards
Risk Analysis
Square Pharmaceuticals PLC. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ৳207.80 |
| 52 Week High | ৳222.70 |
| 52 Week Low | ৳205.80 |
| Beta | 0.17 |
| 1 Month Change | -2.94% |
| 3 Month Change | -4.68% |
| 1 Year Change | -0.95% |
| 3 Year Change | -1.19% |
| 5 Year Change | -5.71% |
| Change since IPO | 9,740.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| SQURPHARMA | BD Pharmaceuticals | BD Market | |
|---|---|---|---|
| 7D | -2.3% | -3.6% | -2.6% |
| 1Y | -1.0% | -17.6% | -19.8% |
Return vs Industry: SQURPHARMA exceeded the BD Pharmaceuticals industry which returned -17.6% over the past year.
Return vs Market: SQURPHARMA exceeded the BD Market which returned -19.8% over the past year.
Price Volatility
| SQURPHARMA volatility | |
|---|---|
| SQURPHARMA Average Weekly Movement | 1.3% |
| Pharmaceuticals Industry Average Movement | 6.4% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in BD Market | 7.8% |
| 10% least volatile stocks in BD Market | 3.1% |
Stable Share Price: SQURPHARMA has not had significant price volatility in the past 3 months.
Volatility Over Time: SQURPHARMA's weekly volatility (1%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1958 | 12,503 | Tapan Chowdhury | www.squarepharma.com.bd |
Square Pharmaceuticals PLC. and its subsidiaries develop, manufacture, and market drugs for health care for various live species in Bangladesh. The company offers generic pharmaceuticals, basic chemicals, and animal health products.
Square Pharmaceuticals PLC. Fundamentals Summary
| SQURPHARMA fundamental statistics | |
|---|---|
| Market cap | ৳184.20b |
| Earnings (TTM) | ৳20.24b |
| Revenue (TTM) | ৳68.81b |
9.1x
P/E Ratio2.7x
P/S RatioIs SQURPHARMA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SQURPHARMA income statement (TTM) | |
|---|---|
| Revenue | ৳68.81b |
| Cost of Revenue | ৳35.60b |
| Gross Profit | ৳33.21b |
| Other Expenses | ৳12.97b |
| Earnings | ৳20.24b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 22.83 |
| Gross Margin | 48.27% |
| Net Profit Margin | 29.41% |
| Debt/Equity Ratio | 1.3% |
How did SQURPHARMA perform over the long term?
See historical performance and comparison